Medicine

Mysimba is a prescription medication in tablet form used for the treatment of overweight and obesity. It contains the active substances naltrexone and bupropion, which together affect the brain's appetite and reward systems.

‍

According to the WHO, overweight and obesity affect nearly 60 per cent of the adult population in Europe, highlighting the need for integrated treatment strategies that combine medical therapy with lifestyle changes (1).

We are in a new era of obesity treatment. GLP-1-based medicines have transformed the landscape – but real success is achieved when medication becomes part of a comprehensive approach that supports the whole person.

Long-term health and weight loss require more than medicine alone. It is when medical treatment is combined with lifestyle change and continuous guidance that meaningful, lasting progress becomes possible (1–2).

Trulicity is a medicine that contains the active substance dulaglutide. It is approved for the treatment of adults with type 2 diabetes to improve glycaemic control as a complement to a healthy diet and physical activity (1). The treatment may also contribute to weight loss (2–4).

Saxenda is a medicine used as support in the treatment of overweight and obesity. It contains the active substance liraglutide, which influences appetite regulation and helps reduce energy intake. When combined with lifestyle changes such as a healthy diet and regular physical activity, the treatment can support clinically significant weight loss (1).

‍

Rybelsus is an oral treatment option used for type 2 diabetes and which in some cases may be relevant within obesity treatment. The medication contains the active substance semaglutide – the same substance as in Ozempic and Wegovy – and works by mimicking the body's own satiety hormone GLP-1. This contributes to reduced appetite, increased feeling of fullness, and delayed gastric emptying.

‍

Mounjaro contains the active substance tirzepatide and is used for the treatment of adults with type 2 diabetes as a supplement to diet and exercise. The medication contributes to lowering blood sugar levels in a glucose-dependent manner.

Mounjaro is also used for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m² with at least one weight-related complication). By affecting the body's appetite regulation, the treatment can contribute to weight loss through reduced energy intake.

Ozempic is a prescription medication used for the treatment of type 2 diabetes as a supplement to diet and exercise. The active substance, semaglutide, contributes to improved blood sugar control and also has an appetite-suppressing effect, which can lead to weight loss.

‍

Wegovy is a prescription medication used for the treatment of obesity and overweight. 

It contains the active substance semaglutide and has shown significant effects on weight loss and cardiometabolic risk factors in clinical studies. By affecting the body's appetite regulation, this treatment can lead to an increased feeling of fullness and reduced energy intake.

Semaglutide is an active pharmaceutical substance used for obesity and type 2 diabetes. Clinical studies have shown significant effects on both weight and metabolic risk factors. Interest in treatment with semaglutide has increased in line with documented results and a growing role in modern obesity care.

Obesity is now one of the world’s greatest public health challenges. According to the WHO, more than 1 billion people worldwide have obesity, including over 650 million adults and 340 million children and adolescents. The prevalence has more than tripled since 1975 and continues to rise in almost every part of the world.

Having severe overweight or obesity is not only about body weight but about health. A high proportion of body fat increases the risk of many different diseases, such as type 2 diabetes, cardiovascular disease, osteoarthritis and certain types of cancer (1).

‍

‍

Obesity in men extends beyond physical health—it intertwines with psychological and societal pressures that shape behavior, self-image, and overall wellbeing.

Obesity significantly impacts men’s hormonal health — particularly testosterone — increasing risks of fatigue, weight gain, and chronic disease; understanding this connection is key to effective treatment and long-term wellbeing.

Excess weight affects men’s physical, hormonal, and mental health in complex ways—understanding these challenges is key to achieving sustainable weight loss and improved wellbeing.

Obesity in men is more than a weight issue — it’s a complex medical condition with far-reaching health risks. From heart disease and liver problems to hormonal and psychological effects, understanding these connections is key to effective prevention and management.

Many men think major weight loss is needed for real results, but even small reductions can greatly boost heart health, hormones, and overall wellbeing.

Discover how Yazen uses blood tests and health screenings to uncover hidden barriers to weight loss and create safe, personalised treatment plans.

At Yazen, we focus on helping women lose weight — a key factor in improving fertility and increasing the chances of pregnancy — through expert, personalised care.

Lipedema is a misunderstood and often misdiagnosed condition that causes painful fat accumulation — Yazen explains the symptoms, causes, and treatment options.

Menopause often brings unexpected weight gain, but with Yazen’s expert support, women can take control of their health and feel confident through every stage.

Polycystic ovary syndrome (PCOS) affects millions of women—and at Yazen, we help you manage symptoms, improve fertility, and take control of your weight and health.

Hypothyroidism is a common condition, especially among British women—and at Yazen, we’re here to help you understand and manage it with confidence.

At Yazen, we support women through the physical, emotional, and hormonal aspects of weight—offering tailored treatment and compassionate care.

New systematic review reveals GLP-1 medication as a novel treatment for binge eating disorders

‍